Sage Therapeutics
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
As the holidays approach, the U.S. Food and Drug Administration (FDA) is getting in a few drug approvals to wrap up the year. This week there are two decision dates, with another that has been delayed for several months. Here’s a look.
An FDA advisory committee overwhelmingly votes in support of Sage’s post-partum depression drug, clearing the way for regulatory approval.
Depression affects almost 20 million Americans yearly and major depressive disorders affect nearly 300 million people worldwide. The annual market for these disorders is approximately $83 billion.
Days after it closed on a $42 million Series A funding round, Karuna Pharmaceuticals has named a new chief executive officer. The company appointed industry veteran and founder of Sage Therapeutics Steven Paul as its new top officer.
Over the years there have been questions surrounding the efficacy of some medications used to treat mental health issues. Last year a Harvard professor argued on CBS’ 60 Minutes that there was little difference between a psychiatric drug and a placebo.
Days after the U.S. Food and Drug Administration provided an expedited path forward for Sage Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million.
Following a meeting with the U.S. Food and Drug Administration Sage Therapeutics is seeing the goal line for potential expedited approval of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression.
JOBS
IN THE PRESS